be released for non-commercial purposes.We also publicly make available the safety and efficacy data relied upon to issue market authorization of drugs and vaccines in relation to COVID-19. the drugs and vaccines that have been authorized for treating COVID-19.a list of applications received for COVID-19-related drugs and vaccines, and their status.This will facilitate timely access to novel drugs and vaccines. We are committed to prioritizing the review of all COVID-19 drug and vaccine applications without compromising on the assessment of their safety, efficacy and quality. Prioritizing COVID-19 applications and being transparent
After the review, we may authorize the drug or vaccine for sale in Canada only if the benefits of the product outweigh the potential risks. They also review the information that will be provided to health care practitioners and consumers about the product. Health Canada scientific reviewers evaluate data to assess the potential benefits and risks of a drug or vaccine. A new drug submission contains detailed scientific information about the drug's safety, efficacy and quality. When a company decides it would like to sell a drug or vaccine in Canada, it files a submission with Health Canada. We also monitor real-world evidence while they are on the market. Health Canada evaluates drugs and vaccines before they can be sold in Canada. Authorization pathways for COVID-19 drugs and vaccines.Prioritizing COVID-19 applications and being transparent.
0 kommentar(er)
